Sub-setting and indication stacking in orphan drugs: a recipe for the future of exclusive rights

Abstract

The present article is, apart from the result of my own work and intellectual effort, also written for a special occasion. Professor Marianne Levin has turned a healthy age, and I have been asked by the current esteemed colleagues at the Stockholm Law Faculty to write a contribution for this special occasion. Scheduling this piece of work into my calendar was difficult, due to a list of other commitments, but I could not possibly refuse the honour, so I accepted. The reader might wonder how Professor Marianne Levin and I could possibly be linked.